Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278851 | 1.00 | ACE (0.53) | ACEFAAHMMECTSGCMA1 | |
| SCHEMBL2576087 | 0.99 | ACE (0.54) | ACEFAAHMMECTSGCMA1 | |
| SCHEMBL2576086 | 0.99 | ACE (0.54) | ACEFAAHMMECTSGCMA1 | |
| SCHEMBL3334668 | 0.98 | ACE (0.53) | ACEFAAHMMECTSGCMA1 | |
| SCHEMBL3334676 | 0.98 | ACE (0.53) | ACEFAAHMMECTSGCMA1 | |
| Zinc Ion SCHEMBL2576092 | 0.90 | CTSG (0.47) | FAAHCTSGCMA1 | |
| Zinc Ion SCHEMBL3334670 | 0.88 | CTSG (0.48) | FAAHCTSGCMA1 | |
| SCHEMBL3278849 | 0.88 | CTSG (0.48) | FAAHCTSGCMA1 | |
| SCHEMBL8257584 | 0.85 | FOLH1 (0.47) | ACEFAAHMMEEPHX2 | |
| SCHEMBL2806565 | 0.84 | FAAH (0.67) | ACEFAAHCTSGCMA1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632089-B2 | Tyrosinase activity inhibitor and external preparation for skin | JO COSMETICS CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20180071239-A1 | TYROSINASE ACTIVITY INHIBITOR AND EXTERNAL PREPARATION FOR SKIN | JO COSMETICS CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | SENJU PHARMACEUTICAL CO. LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7700080-B2 | Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1371640-A1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632089-B2 | Tyrosinase activity inhibitor and external preparation for skin | TYR, SOD1, CAT | ACE 188/4885FAAH 3929/4885MME 685/4885 |
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | TYR, SERPINB1, LPO | ACE 122/4885FAAH 1636/4885MME 163/4885 |
| US-20180071239-A1 | TYROSINASE ACTIVITY INHIBITOR AND EXTERNAL PREPARATION FOR SKIN | TYR, SOD1, CAT | ACE 188/4885FAAH 3929/4885MME 685/4885 |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | TYR, SERPINB1, LPO | ACE 385/4885FAAH 1603/4885MME 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.